Clinical trial · NCT03821857 · RECRUITING · PHASE4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Sponsor: Mayo Clinic
Summary
The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.
Interventions
- 18-F-Flortaucipir · DRUG
Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology
Published eligibility criteria
Verbatim from the registry. Only the site can decide how these apply to a specific patient.
Mayo Clinic Rochester- Inclusion Criteria: * Women who previously participated in this study * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation Mayo Clinic Jacksonville- Inclusion Criteria: * African American Women * Currently aged 60 years and older * More than six months post chemotherapy or major surgery requiring general anesthesia * Willing and able to sign informed consent Exclusion Criteria: * Not able to read and speak English * In hospice * Claustrophobic * If undergoing Tau imaging, cannot have QT Prolongation
Sites (2)
- Mayo Clinic, Jacksonville, Florida · RECRUITING
- Mayo Clinic, Rochester, Minnesota · ENROLLING_BY_INVITATION
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors. Registry data refreshed at most hourly; last update posted 2025-11-24.